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Background: Many autoimmune diseases are associated with variants of HLA genes such as those encoding the
MHC complex. This correlation is not absolute, but may help in understanding of the molecular mechanism of
disease. The purpose of this study was to determine HLA-DR,-DQ alleles in Latvian patients with Lyme borreliosis
and control (healthy) persons. Case patients and control subjects were similar in age, gender and ethnic heritage
and differed only as regards the presence of Borrelia burgdorferi infection. The study included 25 patients with
clinical stage – erythema migrans and 30 control (healthy) persons. HLA genotyping was performed by PCR with
sequence-specific primers.
Results: The results show difference in HLA-DRB1 alleles distribution between patients and control subjects. The
frequencies of HLA-DRB1 *04 (OR 11.24; p < 0.007) and HLA-DRB1 *17 (03) (OR 8.05; p < 0.033) were increased in the
Lyme disease patients. And the frequency of allele DRB1*13 (OR 0.12; p < 0.017) was lower in Borreliosis patients
and higher in control group. But, significant differences in frequencies of HLA-DQ alleles we did not detect.
Conclusions: HLA predisposition to Lyme borreliosis appears not to be limited to HLA molecules, but some HLA-
DR alleles also have a significant influence, and, may have implications in our understanding of pathogenesis of this
disease. In particular, HLA-DRB1*04 and DRB1 *17 (03) may contribute to the Lyme borreliosis development in
Latvian population
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Lyme disease is a tick-borne multisystem disease that
affects primarily the skin, nervous system, heart and
joints. At least three species of Borrelia burgdorferi
sensu lato, namely Borrelia burgdorferi sensu stricto,
Borrelia garinii, and Borrelia afzelii, can cause the
disease.
The illness may evolve in stages, beginning with ery-
thema migrans and progressing through a stage of dis-
semination during which arthritic, neurological, and
cardiac complications may occur. Some patients with
Lyme borreliosis experience recurrent episodes of joint
inflammation for months or years. Although the patho-
genesis of this condition is unclear, several lines of evi-
dence suggest autoimmunity. The histology of synovial
lesions in Lyme borreliosis is similar to that for* Correspondence: Lilija.Kovalcuka@rsu.lv
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distribution, and reproduction in any mediumrheumatoid arthritis (RA) and includes hyperplasia, vas-
cular proliferation, and lymphoid infiltrates [1]. The
majority of individuals with Lyme disease have the
HLA-DRB1*0401 or HLA-DRB1*0101 allele, alleles which
also occur more frequently in patients with RA [2]. Fur-
thermore, while Borrelia burgdorferi DNA can be de-
tected in joint fluid of Lyme disease patients by PCR
prior to treatment with antibiotics, it is unusual to detect
such DNA in synovium or synovial fluid after antibiotic
treatment, especially for patients experiencing recurrent
Lyme arthritis [2,3]. These findings suggest that the
pathogenesis of joint disease in chronic Lyme borreliosis
may be a result of antibody directed against a component
of the Borrelia burgdorferi spirochete that cross-reacts
with synovial tissue.
Lyme disease is the most common vector-borne dis-
ease in the United States [3,4], the incidence remains
high in Latvia also. During last 10 years (2001–2010),
tick-borne encephalitis morbidity in Latvia varies from
6.2 to 22.3 per 100.000 inhabitants (142 to 494 peopletral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Kovalchuka et al. BMC Research Notes 2012, 5:438 Page 2 of 4
http://www.biomedcentral.com/1756-0500/5/438per year). Lyme borreliosis morbidity in Latvia during
the same time period was between 14 and 36.9 per
100.000 inhabitants (328 to 829 people per year). The
largest number of cases of Lyme borreliosis was
recorded in 2010 year - 829 [5]. Latvia is considered to
be an endemic territory; however, people get affected in
other countries of the world as well. The maximum inci-
dence rates in patients were observed in the age group
60–69 [6,7].
In Europe most cases occur in Scandinavia and Cen-
tral Europe. A prospective, population-based survey in
southern Sweden revealed an annual incidence of 69
cases per 100,000 populations [8]. As in the United
States, there were areas of endemicity in which the an-
nual incidence reached 160 per 100.000 inhabitants [8].
A similar study in southern Germany found an annual
incidence of 111 cases per 100,000 inhabitants.
The purpose of this study was to determine HLA-DR,-
DQ molecules in patients with clinical, epidemiological
and laboratory approved Lyme borreliosis diagnosis.
Materials and methods
The study included 25 patients (8 males, 17 females;
aged between 35 and 74 years) with clinical stage –
erythema migrans and 30 control (healthy) persons (12
males, 18 females; aged between 21 and 57 years). All
patients and healthy persons are residents of Latvia. The
clinical diagnosis was confirmed at Infectology Center of
Latvia. Immunogenetic examinations were performed in
Riga Stradiņš University, Clinical Immunology and
Immunogenetic laboratory. The Riga Stradinš University
Ethics Committee approval was obtained (September 9,
2010). And the writteninformed consent for participa-
tion in the study from participants was obtained.
Genomic DNA was extracted from proteinase-K-
treated peripheral blood leukocytes using the routine
“salting-out” method [9,10]. The DNA was stored in TE
buffer (10 ml Tris–HCl, pH 7.5, and 2 ml 0.5 M Na2
EDTA per liter of distilled water). The DNA concentra-
tion, around 100–200 μg/ml, was determined by fluores-
cence with a DNA fluorimeter.
HLA- typing
HLA-DR genotyping by PCR Low-resolution for DRB1*01
to DRB1*18; HLA-DQA1 typing for DQA1*0101 to
DQA1*0601; and HLA-DQB1 typing for DQB1*0201 to
DQB1*0608 was performed by PCR with sequence-
specific primers (PCR–SSP) [10,11]. The reaction mixture
(15 μl) included 1.0 μl DNA, 1.5 μl PCR buffer [50 mM
KCl, 1.5 mM MgCl2, 10 mM Tris–HCl (pH 8.3)], 0.6 μl
dNTPs (25 mmol/l), 1.0 μl specific primers (0.2 mmol/l),
and 0.5 U of the Taq DNA polymerase (Promega). The re-
action mixture was subjected to 35 amplification cycles,
each consisting of one denaturation cycle at 94°C (60 s),seven annealing cycles at 94°C (40 s) and 67°C (15 s), and
final 28 extension cycles at 93°C (10 s) and 65°C (9 s).
PCR products were visualized by agarose-gel electrophor-
esis [10,11]. After addition of 2 M loading buffer, the PCR
reaction mixtures were loaded in agarose gels prestained
with ethidium bromide (0.5 μk/ml gel). Gels were run for
15 min at 10 V/cm gel in 0.5 mM TBE (0.89 M Tris,
0.89 M Boric acid and 0.02 M EDTA in aqueous solution)
buffer and then examined under UV illumination and
recorded [11].
Statistical analysis
The significance of differences in individual subtypes be-
tween patients and controls was assessed by Fisher exact
test for small numbers [12] and with Bonferroni correc-
tion. Odds ratios (OR) and 95% confidence intervals (CI)
were computed by standard methods [12].
Results
Typing of all sixteen alleles DRB1were investigated
(Table 1). The frequency of HLA-DRB1 *04 (OR 11.24;
p < 0.007) and HLA-DRB1 *17(03) (OR 8.05; p < 0.033)
were increased in the Lyme disease patients compared
with the control groups. The frequency of allele
DRB1*13 (OR 0.12; p < 0.017) was lower in Borreliosis
patients and higher in controls. After Bonferroni adjust-
ment the difference was no significant when pc-value
was 0.106, 0.415, and 0.239 (respectively) (Table 1).
Further we focused on the HLA DQA1 and HLA-
DQB1 genotyping. HLA-DQA1 typing for DQA1* 0101,
*0102, *0103, *0201, *0301, *0501, *0401/*0601; and
HLA-DQB1 typing for DQB1* 0201, *0301, *0302,
*0303, *0304, *0305, *0501, *0601, *0602/*0608 alleles
were studied also. We did not detect significant differ-
ences in frequencies of HLA-DQ alleles. Although, the
HLA-DQA1*0501(OR 3.77; p < 0.243), and DQB1*0201
(OR 3.22; p < 0.151) were increased in patients compared
with the control groups, but the difference was no sig-
nificant (data not shown).
Discussion
Lyme disease is a multi-faceted illness, initiated upon infec-
tion with the spirochete Borrelia burgdorferi. One manifest-
ation of the disease is arthritis, which can result in chronic
arthritis in a small subset of exposed individuals [13]. The
prevalence of HLA-DR4 related alleles in these patients is
an indication of an autoimmune process [13,14].
Many autoimmune diseases are linked to variants of
HLA genes such as those encoding the MHC class II com-
plex [15]. Chronic Lyme arthritis is associated with MHC
class II variants that are able to bind to fragments of the
Borrelia burgdorferi protein OspA (outer surface protein
A) encompassing amino acid residues 165 through 173.
Antigen-presenting cells whose MHC class II molecules









50 alleles 60 alleles
*01 0 5 (17%) ND ND
*02 0 2 (7%) ND ND
*03 3 (12%) 4 (13%) 0.89 (0.21-3.83) 0.601
*04 8 (32%) 1 (3%) 11.24 (1.24-74.18) 0.007 0.106
*07 3 (12%) 5 (17%) 0.70 (0.18-2.87) 0.464
*08 2 (8%) 3 (10%) 0.79 (0.14-4.60) 0.586
*09 2 (8%) 3 (10%) 0.79 (0.14-4.60) 0.586
*10 1 (4%) 3 (10%) 0.39 (0.04-3.73) 0.380
*11 6 (24%) 9 (30%) 0.77 (0.31-2.09) 0.648
*12 3 (12%) 4 (13%) 0.89 (0.21-3.83) 0.601
*13 1 (4%) 9 (30%) 0.12 (0.02-1.02) 0.017 0.239
*14 0 2 (7%) ND ND
*15 4 (16%) 1 (3%) 5.13 (0.55-41.58) 0.130
*16 2 (8%) 2 (7%) 1.21 (0.18-8.22) 0.619
*17(03) 6 (24%) 1 (3%) 8.05 (0.90-57.83) 0.033 0.415
*18(03) 3 (12%) 1 (3%) 3.77 (0.39-33.54) 0.243
Abbreviations: ND - not defined; OR (odds ratio); CI (confidence interval); p-value (probability); pc-value (after Bonferroni adjustment).
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T cells that recognize the OspA peptide [16,17].
The first hypothesis that Lyme arthritis may have an
autoimmune component is the demonstration of its as-
sociation with the HLA–DR4 and HLA–DR2 alleles
[14,18]. Patients who have HLA–DRB molecules that
bind an epitope of Borrelia burgdorferi outer surface
protein A (OspA163–175) are more likely to have
chronic arthritis than are patients with other DRB mole-
cules [19,20]. Molecular techniques have identified the
OspA163–175–binding molecules as the rheumatoid
arthritis (RA) alleles (DRB1*0401, *0404, *0405, *0101,
*0102) [21,22] and the DRB5*0101 allele linked to
DRB1*1501 (the former DR2 allele) [22]. Moreover,
patients with chronic arthritis often have T cell recogni-
tion of OspA163–175 [23,24]. In other words, simply
the presence of the DR4 allele was enough to trigger an
inflammatory immune response.
Why is this particular gene so important? The DR al-
lele is responsible for presenting the antigen to the T
cells for an immune system response. When the antigen
is presented to the T cell in the context of the DR4 allele,
T cells are stimulated to produce interferon gamma, an
inflammatory response. In contrast, when the antigen is
presented in the context of the DR11 allele, it stimulates
the production of antibodies, a response that does not
induce inflammation. The antibodies bind to the bacteria
and eliminate it. So somehow the presence of either theDR4 or DR11 allele determines the T cell response —
whether to produce interferon gamma and launch an in-
flammatory attack or to produce antibodies to the anti-
gen, instead [25]. In the case of DR4, once the immune
response has begun, it is self-perpetuating because inter-
feron gamma will stimulate T cells to produce more
interferon gamma. Thus the initial immune response
determines the outcome of the disease in the long run.
In our HLA study, an association was confirmed be-
tween Lyme borreliosis and the HLA-DRB1 *04 and
-DRB1 *17(03) (part of the older HLA-DR3). The distri-
bution of alleles in the patients included in this study
follows the world tendency: HLA-DRB1 *04 and DRB1
*17(03) was the most frequent allele in Caucasian popu-
lation. Thereafter, we began to determine HLA-DQ
alleles in Latvian patients with Lyme arthritis. The HLA-
DQA1*0501 and DQB1*0201 were increased in patients,
but, significant differences in frequencies of HLA-DQ
alleles we did not detect.
Conclusions
These results suggest that the inflammatory events of
the subacute arthritis can set the stage for development
of chronic disease in individuals possessing an HLA sus-
ceptibility allele. In particular, HLA-DRB1*04 and DRB1
*17 (03) may contribute to the Lyme borreliosis develop-
ment in Latvian population, and may have implications
in our understanding of pathogenesis of this disease. To
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alleles in Latvian population and their possible relation-
ship with Borreliosis it is necessary to continue the in-
vestigation and extend the range of persons under
investigation. Treatment for patients with acute manifes-
tations of Lyme disease is well established and effective.
Understanding the pathophysiology of chronic borrelio-
sis and treatment-resistant Lyme arthritis are both major
challenges and a prerequisite for the eventual develop-
ment of effective treatments for these conditions.
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